| Summary of Unaudited Quarterly Financial Information |
Summary of Unaudited Quarterly Financial Information The following is a summary of our unaudited quarterly results for the years ended December 31, 2014 and 2013 (in thousands): | | | | | | | | | | | | | | | | | | | | Quarter Ended | 2014 (Unaudited): | | March 31, | | June 30, | | September 30, | | December 31, | Total revenues(1) | | $ | 11,966 |
| | $ | 18,385 |
| | $ | 14,606 |
| | $ | 30,377 |
| Gross profit on product sales | | $ | 3,048 |
| | $ | 3,570 |
| | $ | 4,476 |
| | $ | 3,997 |
| Total operating expenses | | $ | 37,185 |
| | $ | 33,325 |
| | $ | 33,632 |
| | $ | 34,228 |
| Net loss | | $ | (26,548 | ) | | $ | (16,273 | ) | | $ | (20,280 | ) | | $ | (5,274 | ) | Net loss per share, basic and diluted | | $ | (0.22 | ) | | $ | (0.13 | ) | | $ | (0.16 | ) | | $ | (0.04 | ) | Shares used in computing basic and diluted net loss
per share | | 118,943 |
| | 123,710 |
| | 124,041 |
| | 124,272 |
| | | | | | | | | | | | Quarter Ended | 2013 (Unaudited): | | March 31, | | June 30, | | September 30, | | December 31, | Total revenues | | $ | 11,833 |
| | $ | 14,454 |
| | $ | 16,013 |
| | $ | 12,499 |
| Gross profit on product sales(2) | | $ | 769 |
| | $ | 1,816 |
| | $ | 9,342 |
| | $ | 6,266 |
| Total operating expenses | | $ | 30,330 |
| | $ | 36,574 |
| | $ | 34,507 |
| | $ | 33,822 |
| Net loss | | $ | (19,289 | ) | | $ | (22,912 | ) | | $ | (19,292 | ) | | $ | (21,986 | ) | Net loss per share, basic and diluted | | $ | (0.17 | ) | | $ | (0.20 | ) | | $ | (0.17 | ) | | $ | (0.19 | ) | Shares used in computing basic and diluted net loss
per share | | 112,417 |
| | 112,486 |
| | 112,765 |
| | 113,550 |
|
_______________ | | (1) | Revenues for the quarter ended December 31, 2014 included $15.0 million in revenue under collaborative agreements from the Janssen Collaboration. |
| | (2) | Gross profit on product sales for the quarters ended June 30, 2013, September 30, 2013 and December 31, 2013 excluded manufacturing costs related to the product sales of bulk rHuPH20 for Herceptin SC and HyQvia in the amounts of $0.9 million, $6.5 million and $2.6 million, respectively. Such costs were incurred prior to European marketing approvals for Herceptin SC and HyQvia, and therefore, they were charged to research and development expenses in the periods the costs were incurred. |
|